Gynecologic oncology · 2025
SMARCA4 pathogenic variants: Gynecological cancer histories from a laboratory tested cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Borden Brittany A, Rodriguez-Hernandez Adela, Trottier Magan, Horiguchi Miki, Weyandt Jamie D, Horton Carolyn, Polfus Linda M, Bychkovsky Brittany L, Young Colin C, Garber Judy E, St Laurent Jessica D, Rana Huma Q
Аннотация
OBJECTIVE: To describe the cancer histories of individuals with a SMARCA4 germline pathogenic/likely pathogenic variant (gPV) obtained through clinical laboratory-based testing to aid in informing guidance surrounding surveillance and prevention for individuals with gPV.
METHODS: This retrospective cohort study analyzed individuals with a SMARCA4 gPV identified by multigene panel testing for hereditary cancer at a single commercial clinical laboratory (2014-2024). Descriptive statistics were used to summarize individuals with a gPV in SMARCA4. Age at diagnosis of small cell carcinoma of the ovary hypercalcemic type (SCCOHT) and of unspecified ovarian cancer among individuals with a SMARCA4 gPV was enumerated using cumulative distribution functions.
RESULTS: Among genotyped individuals, 137 had a SMARCA4 gPV. After applying exclusion criteria, 127 individuals were included in the analysis. Individuals with a SMARCA4 gPV were predominately female (74.8 %), and 53.5 % (n = 68) had a history of cancer. Of the females with a cancer history, SCCOHT (17.9 %) and ovarian cancer not otherwise specified (7.4 %) were reported. SCCOHT accounted for 29.8 % of cancer diagnoses among females aged ≤50 years. All SCCOHT cases among individuals with SMARCA4 gPVs were diagnosed by age 40.
CONCLUSION: Our data support the inclusion of SMARCA4 in genetic testing for hereditary early-onset ovarian cancer, enumerate the ages of SCCOHT diagnosis, and highlight the need for prospective penetrance studies to improve counseling and management for patients and their families.
METHODS: This retrospective cohort study analyzed individuals with a SMARCA4 gPV identified by multigene panel testing for hereditary cancer at a single commercial clinical laboratory (2014-2024). Descriptive statistics were used to summarize individuals with a gPV in SMARCA4. Age at diagnosis of small cell carcinoma of the ovary hypercalcemic type (SCCOHT) and of unspecified ovarian cancer among individuals with a SMARCA4 gPV was enumerated using cumulative distribution functions.
RESULTS: Among genotyped individuals, 137 had a SMARCA4 gPV. After applying exclusion criteria, 127 individuals were included in the analysis. Individuals with a SMARCA4 gPV were predominately female (74.8 %), and 53.5 % (n = 68) had a history of cancer. Of the females with a cancer history, SCCOHT (17.9 %) and ovarian cancer not otherwise specified (7.4 %) were reported. SCCOHT accounted for 29.8 % of cancer diagnoses among females aged ≤50 years. All SCCOHT cases among individuals with SMARCA4 gPVs were diagnosed by age 40.
CONCLUSION: Our data support the inclusion of SMARCA4 in genetic testing for hereditary early-onset ovarian cancer, enumerate the ages of SCCOHT diagnosis, and highlight the need for prospective penetrance studies to improve counseling and management for patients and their families.